Citations

Clear

626 citation(s) found for "Mehta, SH".

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
Curti, Brendan D. , Smith, David C. , Rixe, Olivier , Bajor, David L. , Gutierrez, Martin , Kuzel, Timothy M. , Amore, Benny , Grilley‐Olson, Juneko E. , Goel, Sanjay , Gajewski, Thomas Frank , Markovic, Svetomir N. , Mehta, Amitkumar , Guerrero, Abraham, Wang, Zejing , Coveler, Andrew L.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3093-3093

10.1200/jco.2018.36.15_suppl.3093 Get It

Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology’s RTOG 0614.
Deshmukh, Snehal, Brown, Paul D. , Grosshans, David R. , Cerhan, Jane H. , Khuntia, Deepak , Shi, Wenyin , Laack, Nadia N., Chen, Yuhchyau , Curtis, Amarinthia, Laba, Joanna, Mowat, Rex B., Thakrar, Anu, Pugh, Stephanie L. , Wefel, Jeffrey S. , Sulman, Erik P. , Mehta, Minesh P. , Mishra, Mark V. , Suh, John H. , Bruner, Deborah Watkins , Shi, Wenyin

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2065-2065

10.1200/jco.2018.36.15_suppl.2065 Get It

Outcome measures for pediatric laryngotracheal reconstruction: International consensus statement
Balakrishnan, Karthik , Sidell, Douglas R. , Bellia‐Munzon, Gaston F., Boesch, R. Paul , Bromwich, Matthew, Cofer, Shelagh A. , Daines, Cori , Alarcón, Alessandro de , Garabédian, N , Ida, Jonathan B., Leboulanger, Nicolas , Manning, Peter B., Mehta, Deepak, Monnier, Philippe, Myer, Charles M. , Prager, Jeremy D. , Propst, Evan J. , Rahbar, Reza , Russell, John , Rutter, Michael J. , Thierry, Briac , Thompson, Dana M. , Torre, Michele , Varela, Patricio, Vijayasekaran, Shyan , White, David R. , Wineland, Andre , Wood, Robert E. , Wootten, Christopher T. , Zur, Karen B. , Cotton, Robin T., Sidell, Douglas R. , Hart, Catherine K , Leboulanger, Nicolas , Prager, Jeremy D , Zur, Karen , Sidell, Douglas R , Bauman, Nancy M. , Bellía-Munzón, Gastón , Hart, Catherine K. , Preciado, Diego A.

Mayo Clinic

The Laryngoscope | August 28, 2018 | Volume: 129 | Issue: 1 | Pages: 244-255

10.1002/lary.27445 | PMID 30152166 Get It

ObjectivesDevelop multidisciplinary and international consensus on patient, disease, procedural, and perioperative factors, as well as key outcome measures and complications, to be reported for pediatric airway reconstruction studies.MethodsStandard Delphi methods were applied. Participants proposed items in three categories: 1) patient/disease characteristics, 2) procedural/intraoperative/perioperative factors, and 3) outcome measures and complications. Both general and anatomic site‐specific measures were elicited. Participants also suggested specific operations to be encompassed by this project. We then used iterative ranking and review to develop consensus lists via a priori Delphi consensus criteria.ResultsThirty‐three pediatric airway experts from eight countries in North and South America, Europe, and Australia participated, representing otolaryngology (including International Pediatric Otolaryngology Group members), pulmonology, general surgery, and cardiothoracic surgery. Consensus led to inclusion of 19 operations comprising open expansion, resection, and slide procedures of the larynx, trachea, and bronchi as well as three endoscopic procedures. Consensus was achieved on multiple patient/comorbidity (10), disease/stenosis (7), perioperative‐/intraoperative‐/procedure‐related (16) factors. Consensus was reached on multiple outcome and complication measures, both general and site‐specific (8 general, 13 supraglottic, 15 glottic, 17 subglottic, 8 cervical tracheal, 12 thoracic tracheal). The group was able to clarify how each outcome should be measured, with specific instruments defined where applicable.ConclusionThis consensus statement provides a framework to communicate results consistently and reproducibly, facilitating meta‐analyses, quality improvement, transfer of information, and surgeon self‐assessment. It also clarifies expert opinion on which patient, disease, procedural, and outcome measures may be important to consider in any pediatric airway reconstruction patient.Level of Evidence5 Laryngoscope, 129:244–255, 2019
Abstract CT151: TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study
Gondi, Vinai , Ahluwalia, Manmeet S. , Brown, Paul D. , Ahluwalia, Manmeet S , Mehta, Minesh P.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: CT151-CT151

10.1158/1538-7445.am2018-ct151 Get It

Abstract Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality, based on low intensity alternating electric fields. Efficacy of TTFields in non-small cell lung cancer (NSCLC) has been demonstrated in multiple in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma patients. The study [NCT02831959] objectives are to test the efficacy, safety and neurocognitive outcomes of TTFields in this patient population. Patients (N=270) with 1-10 brain metastases (BM) from NSCLC are randomized 1:1 to stereotactic radio surgery (SRS) followed by TTFields or supportive care. Patients are followed-up every two months until 2nd intracranial progression. Patients in the control arm may cross over to TTFields at the time of 2nd intracranial progression. Key inclusion criteria: KPS ≥70, 1 inoperable or 2-10 brain lesions amenable to SRS, optimal standard therapy for the extracranial disease, no brain-directed therapy, no signs of significantly increased intracranial pressure, and no electronic implantable devices in the brain. Endpoints included time to 1st intracranial progression or neurological death (primary); time to neurocognitive failure, HVLT, COWAT and TMT); overall survival; radiological response rate; quality-of-life; and adverse events. Treatment comprised continuous TTFields at 150 kHz for > 18 hours/day applied to the brain within 7 days of SRS. The treatment system is a portable medical device allowing normal daily activities. The device delivers TTFields to the brain using 4 Transducer Arrays, which may be covered by a wig or hat. Patients receive the best standard of care for their systemic disease. Statistical Considerations: This is a prospective, randomized, multicenter study. The sample size (N=270) was calculated using a log-rank test (Lakatos 1988 and 2002) with 80% power at a two sided alpha of 0.05 to detect a hazard ratio of 0.57. Citation Format: Minesh Mehta, Vinai Gondi, Manmeet Ahluwalia,, Paul D. Brown. TTFields and radiosurgery for 1 to 10 brain metastases from NSCLC in the phase III METIS study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT151.
Abstract 223: A meta-analysis of genome-wide association studies of multiple myeloma among African Americans
Du, Zhaohui , Song, Chi , Rand, Kristin A. , Weinhold, Niels , Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Carpten, John D. , Stroup, Antoinette M. , Zhang, Wei , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Olshan, Andrew F. , Chanock, Stephen Jacob , Colditz, Graham A. , Tomasson, Michael H. , Fiala, Mark A. , Marchand, Loı̈c Le , Ziv, Elad , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Cozen, Wendy

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 223-223

10.1158/1538-7445.am2018-223 Get It

Abstract Multiple myeloma (MM) is twice as common in African Americans (AA) compared to European Americans (EA). The reported familial clustering and the elevated MM risk among first-degree relatives of cases implicate genetic susceptibility. Previous genome-wide association studies (GWAS) in EA have identified 16 novel risk loci. In this study, we tested the generalizability of the established risk alleles to AA and conducted a meta-GWAS analysis using two sets of AA to identify additional novel common MM risk variants. In the first study, we genotyped 1,305 incident AA MM cases from the African American Multiple Myeloma Study (AAMMS) using the Illumina HumanCore GWAS array and compared them to 7,078 AA controls from the African Ancestry Prostate Cancer Consortium (AAPC) and African Ancestry Breast Cancer Consortium (AABC) using the Illumina 1M-Duo. In the second study, 95 additional AAMMS cases and 435 AA MM cases from the University of Arkansas for Medical Sciences (UAMS) were genotyped using the Illumina MegaBead Chip and compared to 2,390 AA controls from the Multiethnic Cohort. The Haplotype Reference Consortium (HRC) was used to impute the overlapping typed SNPS from each GWAS case and control set together. Per-allele risk associations were tested for 8,715,278 overlapping genotyped and imputed variants with >1% frequency and >0.8 imputation score using unconditional logistic regression in both sets, and the combined effects were estimated using a fixed-effect meta-analysis. Of the 16 reported risk loci discovered in EA, directional consistency was present for 15 variants; eight of these replicated at nominal significance p<0.05, with the most statistically significant variant being rs4487645 at 7p15.3 (OR=1.38, p=3.56×10-6). AA individuals with polygenic risk scores from these 16 variants (PRS) in the top 10% stratum had a 1.44-fold increased MM risk compared to those with a PRS in the 25th -75th percentiles. Additionally, we identified three suggestive novel loci located at 12q12, 9p24.3 and 9p13.1 at p<1×10-6, with ORs ranging from 1.25-1.55, but none reached genome-wide significance. The variant at 9p24.3 is located in an intron in the KANK1 gene and a correlated SNP in EAs (r2=0.5) is strongly associated with gene expression in neoplastic plasma cells (unpublished, Weinhold and Morgan). Our study replicated most of the reported risk loci discovered among EA, demonstrated that a PRS constructed using the 16 reported risk alleles was associated with MM risk, and provides suggestive evidence for additional loci associated with MM risk in AAs. Citation Format: Zhaohui Du, Chi Song, Kristin Rand, Niels Weinhold, David Van Den Berg, Amie Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward S. Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William Blot, John David Carpten, Antoinette Stroup, Andrew Olshan, Wei Zhang, African Ancestry Breast & Prostate Consortium, Stephen Chanock, Jayesh Mehta, Graham A. Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Loic LeMarchand, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen. A meta-analysis of genome-wide association studies of multiple myeloma among African Americans [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 223.
Proenkephalin (PENK) as a Novel Biomarker for Kidney Function
Struck, Joachim , Wu, Alan H.B. , Zarbock, Alexander , Somma, Salvatore Di , Mehta, Ravindra L. , Nadim, Mitra K. , Maisel, Alan S. , Neath, Sean‐Xavier , Jaffe, Allan S. , Pickkers, Peter , Jaffe, Allan, Mehta, Ravindra L , Beunders, Remi , Koyner, Jay L. , Murray, Patrick T. , Jaffe, Allan S.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 3 | Pages: 400-412

10.1373/jalm.2017.023598 | PMID 33636859 Get It

Abstract Background The assessment of kidney function and detection of acute kidney injury (AKI) remain cumbersome. On the one hand, because of limited accuracy of established tests: The most widely used methods are creatinine based, which lack in sensitivity, as creatinine is not purely filtrated by the kidney and rises relatively late after onset of AKI. On the other hand, because of labor-intensiveness: Gold standard inulin clearance and comparable methods involve intravenous compound infusion, blood sampling at several time points, and have error-sensitive determination methods. In recent years, several biomarkers have been put forward (e.g., NGAL, KIM-1, TIMP-2*IGFBP-7), but clinical implementation is limited up to now. Content Proenkephalin (PENK) represents a new candidate to determine kidney function. This peptide is cleaved from the precursor peptide preproenkephalin A alongside enkephalins (endogenous opioids) and is filtrated in the glomerulus. PENK plasma concentration appears to accurately represent glomerular filtration rate in patients diagnosed with sepsis or cardiac diseases. Moreover, increased PENK concentration is found to be associated with longer-term outcome concerning AKI and cardiac diseases. Lastly, the predominant receptor of enkephalins, the δ-opioid receptor, is expressed with the highest density in the kidney, suggesting that enkephalins could also exert a direct effect on kidney function. Summary In this review, we present an overview of enkephalins and the assessment of kidney function using this possible new functional biomarker PENK and compare it with established and novel biomarkers.
Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non–Small Cell Lung Cancer. Systematic Review and Meta-Analysis
Labarca, Gonzalo , Jantz, Michael A., Mehta, Hiren J. , Majid, Adnan , Fernández-Bussy, Sebastián , Mehta, Hiren J , Labarca, Gonzalo , Folch, Erik E.

Mayo Clinic

Annals of the American Thoracic Society | July 16, 2018 | Volume: 15 | Issue: 10 | Pages: 1205-1216

10.1513/annalsats.201801-045oc | PMID 30011388 Get It

Abstract Rationale Endobronchial ultrasound and transbronchial needle aspiration (EBUS-TBNA) are commonly used for the diagnosis and mediastinal staging of lung cancer. Molecular markers are becoming increasingly important in patients with lung cancer to define targetable mutations suitable for personalized therapy, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species proto-oncogene (ROS1), and programmed death-ligand 1 (PD-L1). Objectives To evaluate the adequacy of EBUS-TBNA–derived tissue for molecular analysis. Methods We searched the MEDLINE, LILACS, www.clinicaltrials.gov, and Epistemonikos databases through January 2018. Data Extraction Two independent reviewers performed the data search, quality assessment, and data extraction. We included both prospective and retrospective studies; risk of bias was evaluated using the ROBINS-I tool. The primary outcome was the proportion of adequate samples obtained by EBUS-TBNA for molecular analysis. Data were pooled by using a binary random effects model. Finally, evidence was rated by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Results A total of 33 studies including 2,698 participants were analyzed. In 28 studies that evaluated EBUS-TBNA for the identification of EGFR mutations, the pooled probability of obtaining a sufficient sample was 94.5% (95% confidence interval CI], 93.2–96.4%). For identification of ALK mutations, the pooled probability was 94.9% (95% CI, 89.4–98.8%). Finally, the prevalence of EGFR mutation was 15.8% (95% CI, 12.1–19.4%), and the prevalence of ALK mutation was 2.77% (95% CI, 1.0–4.8%). Data for ROS1 and PD-L1 mutations were not suitable for meta-analysis. Conclusions EBUS-TBNA has a high yield for molecular analysis of both EGFR and ALK mutations. However, the suitability of TBNA samples for next-generation sequencing is uncertain and should be explored in further studies. Clinical trial registered with PROSPERO (CRD42017080008).
Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice
Qin, Qing , Mehta, Hemal H. , Navarrete, Gerardo, Brandhorst, Sebastian , Wan, Junxiang , Delrio, Silvia , Zhang, Xin , Lerman, Lilach O. , Cohen, Pinchas , Yen, Kelvin , Lerman, Amir , Cohen, Pinchas

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | July 13, 2018 | Volume: 315 | Issue: 5 | Pages: H1127-H1136

10.1152/ajpheart.00685.2017 | PMID 30004252 Get It

Cardiac fibrosis is a biological process that increases with age and contributes to myocardial dysfunction. Humanin (HN) is an endogenous mitochondria-derived peptide that has cytoprotective effects and reduces oxidative stress. The present study aimed to test the hypothesis that chronic supplementation of exogenous HN in middle-aged mice could prevent and reverse cardiac fibrosis and apoptosis in the aging heart. Female C57BL/6N mice at 18 mo of age received 14-mo intraperitoneal injections of vehicle (old group; n = 6) or HN analog (HNG; 4 mg/kg 2 times/wk, old + HNG group, n = 8) and were euthanized at 32 mo of age. C57BL/6N female mice (young group, n = 5) at 5 mo of age were used as young controls. HNG treatment significantly increased the ratio of cardiomyocytes to fibroblasts in aging hearts, as shown by the percentage of each cell type in randomly chosen fields after immunofluorescence staining. Furthermore, the increased collagen deposition in aged hearts was significantly reduced after HNG treatment, as indicated by picrosirius red staining. HNG treatment also reduced in aging mice cardiac fibroblast proliferation (5′-bromo-2-deoxyuridine staining) and attenuated transforming growth factor-β1, fibroblast growth factor-2, and matrix metalloproteinase-2 expression (immunohistochemistry or real-time PCR). Myocardial apoptosis was inhibited in HNG-treated aged mice (TUNEL staining). To decipher the pathway involved in the attenuation of the myocardial fibrosis by HNG, Western blot analysis was done and showed that HNG upregulated the Akt/glycogen synthase kinase -3β pathway in aged mice. Exogenous HNG treatment attenuated myocardial fibrosis and apoptosis in aged mice. The results of the present study suggest a role for the mitochondria-derived peptide HN in the cardioprotection associated with aging. NEW & NOTEWORTHY Cardiac fibrosis is a biological process that increases with age and contributes to myocardial dysfunction. Humanin is an endogenous mitochondria-derived peptide that has cytoprotective effects and reduces oxidative stress. Here, we demonstrate, for the first time, that exogenous humanin treatment attenuated myocardial fibrosis and apoptosis in aging mice. We also detected upregulated Akt/glycogen synthase kinase-3β pathway in humanin analog-treated mice, which might be the mechanism involved in the cardioprotective effect of humanin analog in aging mice.
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma
Ailawadhi, Sikander , Dholaria, Bhagirathbhai , Khurana, Sharad , Sher, Taimur , Alegria, Victoria R., Paulus, Aneel , Ailawadhi, Meghna, Mehta, Aditya , Chanan‐Khan, Asher , Alegria, Victoria, Dholaria, Bhagirathbhai R , Ailawadhi, Sikander , Paulus, Aneel , Roy, Vivek

Mayo Clinic

British Journal of Haematology | July 6, 2018 | Volume: 185 | Issue: 2 | Pages: 347-350

10.1111/bjh.15458 | PMID 29978498 Get It